What to Start: initial combination regimens for the antiretroviral-naive patient | adult and adolescent ARV | ClinicalInfo, Dec 30, 2020. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive?view=full.

Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76:527–31.

Article  Google Scholar 

Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71:e471–7.

CAS  Article  Google Scholar 

Kuo P, Sun H, Chuang Y, Wu P, Liu W, Hung C. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Int J Infect Dis. 2020;92:71–7.

CAS  Article  Google Scholar 

Kerchberger A, Sheth A, Angert C, et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis. 2020;71:593–600.

CAS  Article  Google Scholar 

Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31:1499–500.

Article  Google Scholar 

Burns J, Stirrup O, Dunn D, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS. 2020;34:109–14.

CAS  Article  Google Scholar 

Calza L, Borderi M, Colangeli V, et al. No significant changes in weight and body fat mass in suppressed HIV-infected patients switched to dual combination lamivudine plus dolutegravir or raltegravir. AIDS Res Hum Retroviruses. 2021;37:204–6.

CAS  Article  Google Scholar 

Carr M, Richardson R, Tong W, et al. Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks. AIDS. 2020;34:789–90.

Article  Google Scholar 

Taramasso L, Di Biagio A, Bovis F, et al. Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-infected young adults and adolescents: a 10-year observational study. Microorganisms. 2020;8:864.

CAS  Article  Google Scholar 

Assoumou L, Racine C, Fellahi S, et al. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. AIDS. 2020;34:1859–62.

Article  Google Scholar 

Gomez M, Seybold U, Roider J, Härter G, Bogner J. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)—to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017. Infection. 2019;47:95–102.

CAS  Article  Google Scholar 

Taramasso L, Berruti M, Briano F, Di Biagio A. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS. 2020;34:877–81.

CAS  Article  Google Scholar 

Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa988.

Article  PubMed  PubMed Central  Google Scholar 

Schafer JJ, Sassa KN, O’Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019;6: ofz414.

Article  Google Scholar 

Max B, DeMarais P. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight. Int J STD AIDS. 2021;32:92–5.

CAS  Article  Google Scholar